Evidence map›Paper›PMID 22676371›Full record

ReviewActa psychiatrica Scandinavica2012

Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder.

M G Soeiro-de-Souza, V V Dias, M L Figueira, O V Forlenza, W F Gattaz, C A Zarate, R Machado-Vieira

Registry-linked trialAbstract readReview
In one paragraph

Review in Acta psychiatrica Scandinavica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04998097 (Changes in Serum miRNA and BDNF Levels in Bipolar II Depression Treated by Theta-burst Stimulation), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04998097 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Changes in Serum miRNA and BDNF Levels in Bipolar II Depression Treated by Theta-burst Stimulation: A Randomized Sham-controlled Exploratory Study

TypeinterventionalSponsorKaohsiung Veterans General Hospital.Ran2022 to 2024Enrolled60ConditionsBipolar II Disorder, Most Recent Episode Major DepressiveArmsrepetitive transcranial magnetic stimulation (rTMS), sham repetitive transcranial magnetic stimulation (rTMS)
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 71 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2014
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

M G Soeiro-de-SouzaMood Disorders Unit (GRUDA), Department and Institute of Psychiatry, School of Medicine, University of Sao Paulo (HC-FMUSP), São Paulo, Brazil.
V V Dias
M L Figueira
O V Forlenza
W F Gattaz
C A Zarate
R Machado-Vieira
Universidade de São Paulo · BRHospital de Santa Maria · PTNational Institute of Mental Health · USUniversity of Lisbon · PT

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Target validation of novel therapeutic agents in mood disordersZIAMH002927 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2010 to 2025
$37.1M
Efficacy of an Antiglutamatergic Agents in Treatment-Resistant DepressionZIAMH002828 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2014
$1.6M
Investigation of Antidepressant Efficacy in BPDZ01MH002828 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2003 to 2008
$568k
Intramural NIH HHS Z01 MH002828Intramural NIH HHS Z99 MH999999
6 · The paper itself

Abstract

objectiveBipolar disorder (BD) likely involves, at a molecular and cellular level, dysfunctions of critical neurotrophic, cellular plasticity and resilience pathways and neuroprotective processes. Therapeutic properties of mood stabilizers are presumed to result from a restoration of the function of these altered pathways and processes through a wide range of biochemical and molecular effects. We aimed to review the altered pathways and processes implicated in BD, such as neurotrophic factors, mitogen-activated protein kinases, Bcl-2, phosphoinositol signaling, intracellular calcium and glycogen synthase kinase-3.

methodsWe undertook a literature search of recent relevant journal articles, book chapter and reviews on neurodegeneration and neuroprotection in BD. Search words entered were 'brain-derived neurotrophic factor,''Bcl-2,''mitogen-activated protein kinases,''neuroprotection,''calcium,''bipolar disorder,''mania,' and 'depression.'

resultsThe most consistent and replicated findings in the pathophysiology of BD may be classified as follows: i) calcium dysregulation, ii) mitochondrial/endoplasmic reticulum dysfunction, iii) glial and neuronal death/atrophy and iv) loss of neurotrophic/plasticity effects in brain areas critically involved in mood regulation. In addition, the evidence supports that treatment with mood stabilizers; in particular, lithium restores these pathophysiological changes.

conclusionBipolar disorder is associated with impairments in neurotrophic, cellular plasticity and resilience pathways as well as in neuroprotective processes. The evidence supports that treatment with mood stabilizers, in particular lithium, restores these pathophysiological changes. Studies that attempt to prevent (intervene before the onset of the molecular and cellular changes), treat (minimize severity of these deficits over time), and rectify (reverse molecular and cellular deficits) are promising therapeutic strategies for developing improved treatments for bipolar disorder.

Indexed as

Antimanic AgentsAtrophyBipolar DisorderBrainBrain-Derived Neurotrophic FactorCalciumHumansLithiumMitogen-Activated Protein KinasesNeuronal PlasticityProto-Oncogene Proteins c-bcl-2Signal TransductionAntimanic AgentsBrain-Derived Neurotrophic FactorCalciumLithiumMitogen-Activated Protein KinasesProto-Oncogene Proteins c-bcl-2

Identifiers

PMID22676371
PMCPMC3936785
OpenAlexW2133111244

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.